The estimated Net Worth of Advisors Llcorbimed Capital... is at least $29.8 Million dollars as of 24 June 2022. Advisors Capital owns over 341,971 units of Arcutis Biotherapeutics Inc stock worth over $4,367,294 and over the last 5 years Advisors sold ARQT stock worth over $25,448,578.
Advisors has made over 4 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors sold 341,971 units of ARQT stock worth $7,287,402 on 24 June 2022.
The largest trade Advisors's ever made was selling 878,200 units of Arcutis Biotherapeutics Inc stock on 6 April 2022 worth over $18,161,176. On average, Advisors trades about 568,765 units every 218 days since 2020. As of 24 June 2022 Advisors still owns at least 415,142 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Advisors Capital stock trades at the bottom of the page.
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron, and Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include: